Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition

David Goyard, Bálint Kónya, Aikaterini S. Chajistamatiou, Evangelia D. Chrysina, Jérémy Leroy, Sophie Balzarin, Michel Tournier, Didier Tousch, Pierre Petit, Cédric Duret, Patrick Maurel, L. Somsák, T. Docsa, P. Gergely, Jean Pierre Praly, Jacqueline Azay-Milhau, Sébastien Vidal

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve new d-glucopyranosylidene-spiro-isoxazolines have been prepared from O-peracylated exo-D-glucals by regio- and stereoselective 1,3-dipolar cycloaddition of nitrile oxides generated in situ by treatment of the corresponding oximes with bleach. This mild and direct procedure appeared to be applicable to a broad range of substrates. The corresponding O-unprotected spiro-isoxazolines were evaluated as glycogen phosphorylase (GP) inhibitors and exhibited IC50 values ranging from 1 to 800 μM. Selected inhibitors were further evaluated in vitro using rat and human hepatocytes and exhibited significant inhibitory properties in the primary cell culture. Interestingly, when tested with human hepatocytes, the tetra-O-acetylated spiro-isoxazoline bearing a 2-naphthyl residue showed a much lower IC50 value (2.5 μM), compared to that of the O-unprotected analog (19.95 μM). The most promising compounds were investigated in Zucker fa/fa rat model in acute and sub-chronic assays and decreased hepatic glucose production, which is known to be elevated in type 2 diabetes. This indicates that glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents in the context of type 2 diabetes.

Original languageEnglish
Pages (from-to)444-454
Number of pages11
JournalEuropean Journal of Medicinal Chemistry
Volume108
DOIs
Publication statusPublished - Jan 27 2016

Fingerprint

Glycogen Phosphorylase
Medical problems
Type 2 Diabetes Mellitus
Glucose
Inhibitory Concentration 50
Hepatocytes
Calcium Gluconate
Rats
Nitriles
Bearings (structural)
Oximes
Primary Cell Culture
Cycloaddition Reaction
Glycogen
Hyperglycemia
Oxides
Depolymerization
Cycloaddition
Blood Glucose
Cell culture

Keywords

  • Carbohydrates
  • Glycogen phosphorylase inhibitors
  • Hepatic glucose production
  • Hepatocytes
  • Spiro-isoxazolines
  • Type 2 diabetes
  • Zucker rats

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Cite this

Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition. / Goyard, David; Kónya, Bálint; Chajistamatiou, Aikaterini S.; Chrysina, Evangelia D.; Leroy, Jérémy; Balzarin, Sophie; Tournier, Michel; Tousch, Didier; Petit, Pierre; Duret, Cédric; Maurel, Patrick; Somsák, L.; Docsa, T.; Gergely, P.; Praly, Jean Pierre; Azay-Milhau, Jacqueline; Vidal, Sébastien.

In: European Journal of Medicinal Chemistry, Vol. 108, 27.01.2016, p. 444-454.

Research output: Contribution to journalArticle

Goyard, D, Kónya, B, Chajistamatiou, AS, Chrysina, ED, Leroy, J, Balzarin, S, Tournier, M, Tousch, D, Petit, P, Duret, C, Maurel, P, Somsák, L, Docsa, T, Gergely, P, Praly, JP, Azay-Milhau, J & Vidal, S 2016, 'Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition', European Journal of Medicinal Chemistry, vol. 108, pp. 444-454. https://doi.org/10.1016/j.ejmech.2015.12.004
Goyard, David ; Kónya, Bálint ; Chajistamatiou, Aikaterini S. ; Chrysina, Evangelia D. ; Leroy, Jérémy ; Balzarin, Sophie ; Tournier, Michel ; Tousch, Didier ; Petit, Pierre ; Duret, Cédric ; Maurel, Patrick ; Somsák, L. ; Docsa, T. ; Gergely, P. ; Praly, Jean Pierre ; Azay-Milhau, Jacqueline ; Vidal, Sébastien. / Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition. In: European Journal of Medicinal Chemistry. 2016 ; Vol. 108. pp. 444-454.
@article{d479cfe40d6c45359139688a86416ccf,
title = "Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition",
abstract = "Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve new d-glucopyranosylidene-spiro-isoxazolines have been prepared from O-peracylated exo-D-glucals by regio- and stereoselective 1,3-dipolar cycloaddition of nitrile oxides generated in situ by treatment of the corresponding oximes with bleach. This mild and direct procedure appeared to be applicable to a broad range of substrates. The corresponding O-unprotected spiro-isoxazolines were evaluated as glycogen phosphorylase (GP) inhibitors and exhibited IC50 values ranging from 1 to 800 μM. Selected inhibitors were further evaluated in vitro using rat and human hepatocytes and exhibited significant inhibitory properties in the primary cell culture. Interestingly, when tested with human hepatocytes, the tetra-O-acetylated spiro-isoxazoline bearing a 2-naphthyl residue showed a much lower IC50 value (2.5 μM), compared to that of the O-unprotected analog (19.95 μM). The most promising compounds were investigated in Zucker fa/fa rat model in acute and sub-chronic assays and decreased hepatic glucose production, which is known to be elevated in type 2 diabetes. This indicates that glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents in the context of type 2 diabetes.",
keywords = "Carbohydrates, Glycogen phosphorylase inhibitors, Hepatic glucose production, Hepatocytes, Spiro-isoxazolines, Type 2 diabetes, Zucker rats",
author = "David Goyard and B{\'a}lint K{\'o}nya and Chajistamatiou, {Aikaterini S.} and Chrysina, {Evangelia D.} and J{\'e}r{\'e}my Leroy and Sophie Balzarin and Michel Tournier and Didier Tousch and Pierre Petit and C{\'e}dric Duret and Patrick Maurel and L. Soms{\'a}k and T. Docsa and P. Gergely and Praly, {Jean Pierre} and Jacqueline Azay-Milhau and S{\'e}bastien Vidal",
year = "2016",
month = "1",
day = "27",
doi = "10.1016/j.ejmech.2015.12.004",
language = "English",
volume = "108",
pages = "444--454",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Elsevier Masson SAS",

}

TY - JOUR

T1 - Glucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibition

AU - Goyard, David

AU - Kónya, Bálint

AU - Chajistamatiou, Aikaterini S.

AU - Chrysina, Evangelia D.

AU - Leroy, Jérémy

AU - Balzarin, Sophie

AU - Tournier, Michel

AU - Tousch, Didier

AU - Petit, Pierre

AU - Duret, Cédric

AU - Maurel, Patrick

AU - Somsák, L.

AU - Docsa, T.

AU - Gergely, P.

AU - Praly, Jean Pierre

AU - Azay-Milhau, Jacqueline

AU - Vidal, Sébastien

PY - 2016/1/27

Y1 - 2016/1/27

N2 - Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve new d-glucopyranosylidene-spiro-isoxazolines have been prepared from O-peracylated exo-D-glucals by regio- and stereoselective 1,3-dipolar cycloaddition of nitrile oxides generated in situ by treatment of the corresponding oximes with bleach. This mild and direct procedure appeared to be applicable to a broad range of substrates. The corresponding O-unprotected spiro-isoxazolines were evaluated as glycogen phosphorylase (GP) inhibitors and exhibited IC50 values ranging from 1 to 800 μM. Selected inhibitors were further evaluated in vitro using rat and human hepatocytes and exhibited significant inhibitory properties in the primary cell culture. Interestingly, when tested with human hepatocytes, the tetra-O-acetylated spiro-isoxazoline bearing a 2-naphthyl residue showed a much lower IC50 value (2.5 μM), compared to that of the O-unprotected analog (19.95 μM). The most promising compounds were investigated in Zucker fa/fa rat model in acute and sub-chronic assays and decreased hepatic glucose production, which is known to be elevated in type 2 diabetes. This indicates that glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents in the context of type 2 diabetes.

AB - Glycogen phosphorylase (GP) is a target for the treatment of hyperglycaemia in the context of type 2 diabetes. This enzyme is responsible for the depolymerization of glycogen into glucose thereby affecting the levels of glucose in the blood stream. Twelve new d-glucopyranosylidene-spiro-isoxazolines have been prepared from O-peracylated exo-D-glucals by regio- and stereoselective 1,3-dipolar cycloaddition of nitrile oxides generated in situ by treatment of the corresponding oximes with bleach. This mild and direct procedure appeared to be applicable to a broad range of substrates. The corresponding O-unprotected spiro-isoxazolines were evaluated as glycogen phosphorylase (GP) inhibitors and exhibited IC50 values ranging from 1 to 800 μM. Selected inhibitors were further evaluated in vitro using rat and human hepatocytes and exhibited significant inhibitory properties in the primary cell culture. Interestingly, when tested with human hepatocytes, the tetra-O-acetylated spiro-isoxazoline bearing a 2-naphthyl residue showed a much lower IC50 value (2.5 μM), compared to that of the O-unprotected analog (19.95 μM). The most promising compounds were investigated in Zucker fa/fa rat model in acute and sub-chronic assays and decreased hepatic glucose production, which is known to be elevated in type 2 diabetes. This indicates that glucose-based spiro-isoxazolines can be considered as anti-hyperglycemic agents in the context of type 2 diabetes.

KW - Carbohydrates

KW - Glycogen phosphorylase inhibitors

KW - Hepatic glucose production

KW - Hepatocytes

KW - Spiro-isoxazolines

KW - Type 2 diabetes

KW - Zucker rats

UR - http://www.scopus.com/inward/record.url?scp=84950153946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950153946&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2015.12.004

DO - 10.1016/j.ejmech.2015.12.004

M3 - Article

C2 - 26708111

AN - SCOPUS:84950153946

VL - 108

SP - 444

EP - 454

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -